Preclinical Efficacy Testing of New Drug Candidates-Reference-Cited by-同舟云学术

Preclinical Efficacy Testing of New Drug Candidates

Published:2017-05-19 Issue:3 Volume:5 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Nuermberger Eric L.¹

Affiliation:

1. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, and Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231-1002

Abstract

ABSTRACT This is a review of the preclinical efficacy testing of new antituberculosis drug candidates. It describes existing dynamic in vitro and in vivo models of antituberculosis chemotherapy and their utility in preclinical evaluations of promising new drugs and combination regimens, with an effort to highlight recent developments. Emphasis is given to the integration of quantitative pharmacokinetic/pharmacodynamic analyses and the impact of lesion pathology on drug efficacy. Discussion also includes in vivo models of chemotherapy of latent tuberculosis infection.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/microbiolspec.TBTB2-0034-2017

Reference169 articles.

1. World Health Organization. 2016. Global tuberculosis report 2016. http://www.who.int/tb/publications/global_report/en/.

2. Cegielski JP Dalton T Yagui M Wattanaamornkiet W Volchenkov GV Via LE Van Der Walt M Tupasi T Smith SE Odendaal R Leimane V Kvasnovsky C Kuznetsova T Kurbatova E Kummik T Kuksa L Kliiman K Kiryanova EV Kim H Kim CK Kazennyy BY Jou R Huang WL Ershova J Erokhin VV Diem L Contreras C Cho SN Chernousova LN Chen MP Caoili JC Bayona J Akksilp S Global Preserving Effective TB Treatment Study (PETTS) Investigators. 2014. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 59: 1049–1063 http://dx.doi.org/10.1093/cid/ciu572.

3. Cegielski JP Kurbatova E van der Walt M Brand J Ershova J Tupasi T Caoili JC Dalton T Contreras C Yagui M Bayona J Kvasnovsky C Leimane V Kuksa L Chen MP Via LE Hwang SH Wolfgang M Volchenkov GV Somova T Smith SE Akksilp S Wattanaamornkiet W Kim HJ Kim CK Kazennyy BY Khorosheva T Kliiman K Viiklepp P Jou R Huang AS Vasilyeva IA Demikhova OV Global PETTS Investigators. 2016. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis 62: 418–430. [PubMed]

4. Diacon AH Pym A Grobusch MP de los Rios JM Gotuzzo E Vasilyeva I Leimane V Andries K Bakare N De Marez T Haxaire-Theeuwes M Lounis N Meyvisch P De Paepe E van Heeswijk RP Dannemann B TMC207-C208 Study Group. 2014. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371: 723–732 http://dx.doi.org/10.1056/NEJMoa1313865.

5. Lienhardt C Lönnroth K Menzies D Balasegaram M Chakaya J Cobelens F Cohn J Denkinger CM Evans TG Källenius G Kaplan G Kumar AM Matthiessen L Mgone CS Mizrahi V Mukadi YD Nguyen VN Nordström A Sizemore CF Spigelman M Squire SB Swaminathan S Van Helden PD Zumla A Weyer K Weil D Raviglione M. 2016. Translational research for tuberculosis elimination: priorities challenges and actions. PLoS Med 13: e1001965 http://dx.doi.org/10.1371/journal.pmed.1001965.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in Viral Vector-Based Vaccines for Tuberculosis: A Patent Review (2010–2023);Vaccines;2024-08-02

2. Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations;Tuberculosis;2024-07

3. Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis;Antimicrobial Agents and Chemotherapy;2024-04-03

4. Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis;2024-03-14

5. Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease;Nature Reviews Drug Discovery;2024-02-28